MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Most important demo targets were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, even though one of... https://andrewh665xjt9.plpwiki.com/user